Cullinan Oncology Inc
NASDAQ:CGEM

Watchlist Manager
Cullinan Oncology Inc Logo
Cullinan Oncology Inc
NASDAQ:CGEM
Watchlist
Price: 15.55 USD -4.13% Market Closed
Market Cap: 901.6m USD
Have any thoughts about
Cullinan Oncology Inc?
Write Note

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of CGEM.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CGEM Intrinsic Value
Not Available
Base Case Scenario
How do you feel about CGEM?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Cullinan Oncology Inc

Provide an overview of the primary business activities
of Cullinan Oncology Inc.

What unique competitive advantages
does Cullinan Oncology Inc hold over its rivals?

What risks and challenges
does Cullinan Oncology Inc face in the near future?

Has there been any significant insider trading activity
in Cullinan Oncology Inc recently?

Show all valuation multiples
for Cullinan Oncology Inc.

Provide P/S
for Cullinan Oncology Inc.

Provide P/E
for Cullinan Oncology Inc.

Provide P/OCF
for Cullinan Oncology Inc.

Provide P/FCFE
for Cullinan Oncology Inc.

Provide P/B
for Cullinan Oncology Inc.

Provide EV/S
for Cullinan Oncology Inc.

Provide EV/GP
for Cullinan Oncology Inc.

Provide EV/EBITDA
for Cullinan Oncology Inc.

Provide EV/EBIT
for Cullinan Oncology Inc.

Provide EV/OCF
for Cullinan Oncology Inc.

Provide EV/FCFF
for Cullinan Oncology Inc.

Provide EV/IC
for Cullinan Oncology Inc.

Show me price targets
for Cullinan Oncology Inc made by professional analysts.

What are the Revenue projections
for Cullinan Oncology Inc?

How accurate were the past Revenue estimates
for Cullinan Oncology Inc?

What are the Net Income projections
for Cullinan Oncology Inc?

How accurate were the past Net Income estimates
for Cullinan Oncology Inc?

What are the EPS projections
for Cullinan Oncology Inc?

How accurate were the past EPS estimates
for Cullinan Oncology Inc?

What are the EBIT projections
for Cullinan Oncology Inc?

How accurate were the past EBIT estimates
for Cullinan Oncology Inc?

Compare the revenue forecasts
for Cullinan Oncology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cullinan Oncology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cullinan Oncology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cullinan Oncology Inc compared to its peers.

Compare the P/E ratios
of Cullinan Oncology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cullinan Oncology Inc with its peers.

Analyze the financial leverage
of Cullinan Oncology Inc compared to its main competitors.

Show all profitability ratios
for Cullinan Oncology Inc.

Provide ROE
for Cullinan Oncology Inc.

Provide ROA
for Cullinan Oncology Inc.

Provide ROIC
for Cullinan Oncology Inc.

Provide ROCE
for Cullinan Oncology Inc.

Provide Gross Margin
for Cullinan Oncology Inc.

Provide Operating Margin
for Cullinan Oncology Inc.

Provide Net Margin
for Cullinan Oncology Inc.

Provide FCF Margin
for Cullinan Oncology Inc.

Show all solvency ratios
for Cullinan Oncology Inc.

Provide D/E Ratio
for Cullinan Oncology Inc.

Provide D/A Ratio
for Cullinan Oncology Inc.

Provide Interest Coverage Ratio
for Cullinan Oncology Inc.

Provide Altman Z-Score Ratio
for Cullinan Oncology Inc.

Provide Quick Ratio
for Cullinan Oncology Inc.

Provide Current Ratio
for Cullinan Oncology Inc.

Provide Cash Ratio
for Cullinan Oncology Inc.

What is the historical Revenue growth
over the last 5 years for Cullinan Oncology Inc?

What is the historical Net Income growth
over the last 5 years for Cullinan Oncology Inc?

What is the current Free Cash Flow
of Cullinan Oncology Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cullinan Oncology Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cullinan Oncology Inc

Current Assets 677.8m
Cash & Short-Term Investments 662.5m
Other Current Assets 15.3m
Non-Current Assets 3.4m
PP&E 3m
Other Non-Current Assets 460k
Current Liabilities 23.5m
Accounts Payable 1.6m
Accrued Liabilities 21.9m
Non-Current Liabilities 1.5m
Other Non-Current Liabilities 1.5m
Efficiency

Earnings Waterfall
Cullinan Oncology Inc

Revenue
0 USD
Operating Expenses
-183.7m USD
Operating Income
-183.7m USD
Other Expenses
41.6m USD
Net Income
-142.2m USD

Free Cash Flow Analysis
Cullinan Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CGEM Profitability Score
Profitability Due Diligence

Cullinan Oncology Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Cullinan Oncology Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

CGEM Solvency Score
Solvency Due Diligence

Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CGEM Price Targets Summary
Cullinan Oncology Inc

Wall Street analysts forecast CGEM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CGEM is 33.37 USD with a low forecast of 28.28 USD and a high forecast of 42 USD.

Lowest
Price Target
28.28 USD
82% Upside
Average
Price Target
33.37 USD
115% Upside
Highest
Price Target
42 USD
170% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CGEM?

Click here to dive deeper.

Dividends

Cullinan Oncology Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CGEM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CGEM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Cullinan Oncology Inc Logo
Cullinan Oncology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

918.4m USD

Dividend Yield

0%

Description

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

Contact

MASSACHUSETTS
Cambridge
One Main Street, Suite 520
+16174104650.0

IPO

2021-01-08

Employees

31

Officers

See Also

Discover More